×
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
S&P 500   3,785.38 (-0.88%)
DOW   30,775.43 (-0.82%)
QQQ   280.28 (-1.24%)
AAPL   136.72 (-1.80%)
MSFT   256.83 (-1.32%)
META   161.25 (-1.64%)
GOOGL   2,179.26 (-2.45%)
AMZN   106.21 (-2.49%)
TSLA   673.42 (-1.76%)
NVDA   151.59 (-2.46%)
NIO   21.72 (-0.64%)
BABA   113.68 (-2.03%)
AMD   76.47 (-1.95%)
MU   55.28 (-1.32%)
CGC   2.85 (-18.57%)
T   20.96 (+0.05%)
GE   63.67 (-0.03%)
F   11.13 (-3.39%)
DIS   94.40 (-1.31%)
AMC   13.55 (-0.73%)
PFE   52.43 (+2.93%)
PYPL   69.84 (-2.28%)
NFLX   174.87 (-1.96%)
NASDAQ:AGEN

Agenus Stock Forecast, Price & News

$1.94
-0.10 (-4.90%)
(As of 06/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.86
$2.03
50-Day Range
$1.30
$2.13
52-Week Range
$1.25
$6.79
Volume
4.60 million shs
Average Volume
4.47 million shs
Market Capitalization
$548.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.00
30 days | 90 days | 365 days | Advanced Chart

Receive AGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agenus and its competitors with MarketBeat's FREE daily newsletter.

AGEN Stock Forecast (MarketRank)

Overall MarketRank

2.09 out of 5 stars

Medical Sector

503rd out of 1,433 stocks

Biological Products, Except Diagnostic Industry

84th out of 217 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
Agenus logo

About Agenus (NASDAQ:AGEN)

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

AGEN Stock News Headlines

Why Agenus Stock Is Soaring Today
Agenus (NASDAQ:AGEN) Stock Price Up 12.1%
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:AGEN
CUSIP
00847G70
Employees
441
Year Founded
N/A

Company Calendar

Last Earnings
5/10/2022
Today
6/30/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$11.00
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$8.00
Forecasted Upside/Downside
+467.0%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
2 Analysts

Profitability

Net Income
$-23.93 million
Pretax Margin
-8.04%

Debt

Sales & Book Value

Annual Sales
$295.67 million
Book Value
$0.19 per share

Miscellaneous

Free Float
268,150,000
Market Cap
$548.75 million
Optionable
Optionable
Beta
1.27














Agenus Frequently Asked Questions

Should I buy or sell Agenus stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Agenus in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Agenus stock.
View analyst ratings for Agenus
or view top-rated stocks.

What is Agenus' stock price forecast for 2022?

2 brokers have issued 12-month price objectives for Agenus' shares. Their AGEN stock forecasts range from $8.00 to $14.00. On average, they expect Agenus' stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 467.0% from the stock's current price.
View analysts' price targets for Agenus
or view top-rated stocks among Wall Street analysts.

How has Agenus' stock price performed in 2022?

Agenus' stock was trading at $3.22 at the beginning of the year. Since then, AGEN stock has decreased by 39.8% and is now trading at $1.94.
View the best growth stocks for 2022 here
.

When is Agenus' next earnings date?

Agenus is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Agenus
.

How were Agenus' earnings last quarter?

Agenus Inc. (NASDAQ:AGEN) announced its earnings results on Tuesday, May, 10th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10. The biotechnology company had revenue of $25.94 million for the quarter, compared to analysts' expectations of $17.35 million. During the same period in the previous year, the business earned ($0.27) EPS.
View Agenus' earnings history
.

Who are Agenus' key executives?

Agenus' management team includes the following people:
  • Dr. Garo H. Armen Ph.D., Founder, Exec. Chairman & CEO (Age 69, Pay $1.28M)
  • Ms. Christine M. Klaskin, VP of Fin., Principal Financial Officer & Principal Accounting Officer (Age 56, Pay $360.51k) (LinkedIn Profile)
  • Dr. Steven J. O'Day M.D., Ph.D., Chief Medical Officer (Age 60, Pay $1.44M)
  • Dr. Jennifer S. Buell Ph.D., Pres & CEO of MiNK Therapeutics (Age 47, Pay $917.25k)
  • Craig Winter, Chief Information Officer
  • Regina Grebla Ph.D., VP of Investor Relations & Communications
  • Ms. Tracy Mazza Clemente, Chief People Officer
  • John Castle, Head of Translational Medicine & Bioinformatics
  • Ms. Julie DeSander, Chief Bus. Officer
  • Mr. Paulo Moreira, Global Head of Clinical Operations

What is Garo H. Armen's approval rating as Agenus' CEO?

2 employees have rated Agenus CEO Garo H. Armen on Glassdoor.com. Garo H. Armen has an approval rating of 56% among Agenus' employees. This puts Garo H. Armen in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Agenus own?

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $1.94.

How much money does Agenus make?

Agenus (NASDAQ:AGEN) has a market capitalization of $548.75 million and generates $295.67 million in revenue each year. The biotechnology company earns $-23.93 million in net income (profit) each year or ($0.10) on an earnings per share basis.

How many employees does Agenus have?

Agenus employs 441 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The official website for Agenus is agenusbio.com. The biotechnology company can be reached via phone at (781) 674-4400, via email at [email protected], or via fax at 781-674-4200.

This page (NASDAQ:AGEN) was last updated on 6/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.